Sarepta Therapeutics Stock
€17.47
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Sarepta
sharewise wants to provide you with the best news and tools for Sarepta, so we directly link to the best financial data sources.
Financials
News
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
In another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular dystrophy (DMD) treatment ELEVIDYS. The patient passed away due to acute
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
Investors searching for high-quality opportunities in the pharmaceutical space should keep a close eye on stocks trading at extremely oversold levels. One of the most popular ways to measure this
Can Solid Biosciences Challenge Sarepta in the DMD Market?
When it comes to treating Duchenne muscular dystrophy (DMD), big news recently surfaced. DMD is a muscle disease. It usually first shows up in boys aged two to five years. Genetic alterations
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Shares of biotech company Solid Biosciences (NASDAQ: SLDB) skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%. So, what information came
2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying
Fundamental investing wisdom tells us to buy stocks with potential when they are trading at a lower valuation. But when a company's prospects look dim, its stock isn't going to be attractive even
Is This Stock a Buy After a Massive 20% Drop in 1 Day?
Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company's performance over the past six months had already been unimpressive
Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Sarepta Therapeutics (NASDAQ: SRPT)Q4 2024 Earnings CallFeb 26, 2025, 4:30 p.m. ET
Operator
Source Fool.com
2 Growth Stocks to Buy Hand Over Fist in February
Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in other industries -- even in healthcare, a sector some investors might